VACCINE EFFECTIVENESS AGAINST INFECTIONS TRIGGERING AUTOIMMUNE DISEASE
Dr Deborah Burnett,
Scientia Senior Lecturer & Laboratory Head
UNSW Sydney, Australia
RESEARCHER PROFILE
Filmed in Sydney, Australia | April 2026
Dr Deborah Burnett is a Scientia Senior Lecturer and Laboratory Head at UNSW, where she leads a multidisciplinary research program spanning mechanistic immunology and translational vaccinology. Her work focuses on understanding how immune responses can protect against challenging infectious threats, including bacterial infections and infections associated with autoimmune disease.
After completing her PhD in 2019, Dr Burnett established her first independent group at the Garvan Institute in 2022 and launched her laboratory at UNSW in 2024. Her research, published in major research journals including Science and Immunity, has helped redefine how self-reactive B cells contribute to protective immunity and is now shaping new approaches to prevention and cure of infections linked to autoimmunity.
Her contributions to research leadership and translation have been recognised through the NSW Premier’s Prize for Early Career Researcher of the Year, Research Australia’s Discovery Award, the Australian L’Oréal-UNESCO For Women in Science Fellowship, a Young Tall Poppy Award, the Marie Krogh Prize for Women in Science, and selection as an International Union of Immunological Societies Rising Star. Through the Snow Fellowship, Dr Burnett and her team aim to develop new ways to distinguish protective from harmful immune responses, advancing safer vaccines, diagnostics and therapies for vulnerable communities affected by infection-associated autoimmune disease.
Source: Supplied
You Might also like
-
Visceral pain and the gut-brain axis
Professor Stuart Brierley is Director of the Visceral Pain Research Group, Director of the Hopwood Centre for Neurobiology, and Theme co-Leader of Lifelong Health at the South Australian Health and Medical Research Institute (SAHMRI).
Prof Brierley is an international expert on the ‘gut-brain axis’ and chronic visceral pain mechanisms. Current investigations are on a individual cell type called the enterochromaffin cell, and it helps signal pain and anxiety from the gastrointestinal tract to the brain.
-
Targeting chemotherapy resistance in ovarian cancer patients
Dr Alex Cole, from the Centenary Institute’s Centre for Biomedical AI, is now leading the research focused on developing a new treatment to counteract a protein called follistatin (FST), known for making ovarian cancer cells resistant to chemotherapy.
By employing cutting-edge molecular biology and directed evolution techniques, the project aims to create nanobodies—small, precise molecules—that can block FST. If successful, these nanobodies could enhance the effectiveness of chemotherapy and improve ovarian cancer treatment rates.
-
Dr Lisa Melton
RESEARCH IN SANFILIPPO
@ SANFILIPPO CHILDREN’S FOUNDATION
SYDNEY, NEW SOUTH WALES, AUSTRALIA
https://orcid.org/0000-0002-5642-3315